
The Danish Medicines Council, which decides whether new medicines should be accepted for widespread use at Danish hospitals, will decide whether to expand the use of Spinraza (nusinersen) to more patients at a video meeting on May 13, the council reports.
The case is being reopened after Biogen, who markets Spinraza, lowered the price of the drug, which is currently used to treat patients with spinal muscular atrophy (SMA), and released new data about its effectiveness.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app